Global healthcare company Organon today stated it has launched with a singular vision – “to make a better and healthier every day for every woman”.

With a majority-female leadership team, the company will be headquartered in the US, with offices across the globe including one in Shoreditch, London. Organon has more than 60 products and says it caters for people in more than 140 countries, with nearly 80% of its approximately $6.5 billion in annual revenue generated outside the US.

Simon Nicholson is the managing director of Organon UK and ENI cluster (the UK, Ireland, Israel, Sweden, Denmark, Norway, Finland, Latvia, Lithuania, Estonia and Iceland). He said: “It’s exciting to take the helm in a new and vibrant company with such a strong purpose; a commitment to improving health outcomes for women. New acquisitions and partnerships will help Organon expand beyond our core strengths in contraceptives and fertility to meet the health needs of women at all stages of her life. This will be fuelled by a refreshed focus on our women’s health portfolio, further biosimilar launches, and a renewed energy put behind our trusted dermatology, pain, respiratory and cardiovascular brands.”

“Our strength will come not only from our medicines and solutions but from the diverse team of Organon founders we have gathered to launch this unique company. We are all personally invested in this opportunity and what we do really matters.”

Organon stated it will explore new opportunities and partnerships across its three main pillars: women’s health, biosimilars and established brands.

For women’s health Organon has a team focusing on improving access to contraceptive and fertility products, and a comprehensive education and training programme to help women and healthcare professionals understand the choices available to them. There is a continued shift toward long-acting reversible contraceptives and a large fertility market with untapped potential driven by changing social demographics.

For biosimilars, Organon stated that this is a dynamic market with multiple launch opportunities in the coming years, which it sees as a core area of growth with the potential to deliver value for Organon, the NHS and patients in the UK.

Organon said its established brands portfolio will be reinvigorated to maximise market-leading, well-known brands that span key therapy areas such as cardiovascular, respiratory, pain, bone and dermatology.

Irina Spirieva, Organon’s commercial operations lead, UK and ENI, said: “For far too long women have been told to accept many common conditions, such as heavy, painful, and irregular menstrual bleeding, incontinence and menopause. Organon’s mission is to change this. We believe that by identifying diseases earlier and modifying the course of diseases or health conditions, we can improve the quality of life for women at every stage of their lives.”

Date published: June 3, 2021

Subscriber content

To get unlimited access subscribe today


Already a subscriber? Login